Theravance Biopharma, Inc. Income Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of operations

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
Viatris collaboration agreement
Viatris royalties (Non-US)
Collaboration Agreement
Licensing revenue
Licensing and Milestone
Total revenues
Expenses:
Research and development
Selling, general and administrative
Restructuring and related expenses
Research and development
Selling, general and administrative
Total restructuring and related expenses

Impairment of long-lived assets (non-cash)
Total expenses
Loss from operations
Income from investment in TRC, LLC
Interest expense
Loss on extinguishment of debt
TRELEGY milestone income
Interest expense (non-cash)
Interest and other income, net
Income (loss) before income taxes
Provision for income tax benefit (expense)
Net loss from continuing operations
Income from discontinued operations before income taxes
Provision for income tax expense
Net income from discontinued operations
Net income (loss)
Continuing operations - basic (in dollars per share)
Discontinued operations - basic (in dollars per share)
Net income (loss) per share:
Net income (loss) per share - basic (in dollars per share)
Net income (loss) per share - diluted (in dollars per share)
Shares used to compute net income (loss) per share - basic (in shares)
Shares used to compute net income (loss) per share - diluted (in shares)
Share-based compensation expense
Research and development
Selling, general and administrative
Restructuring and related expenses
Total share-based compensation expense

Comments